BiotechTube

E7766

Phase 1Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Urinary Bladder Neoplasms

Conditions

Urinary Bladder Neoplasms

Trial Timeline

Feb 13, 2020 → Sep 29, 2022

NCT ID
NCT04109092

About E7766

E7766 is a phase 1 stage product being developed by Eisai for Urinary Bladder Neoplasms. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04109092. Target conditions include Urinary Bladder Neoplasms.

What happened to similar drugs?

8 of 20 similar drugs in Urinary Bladder Neoplasms were approved

Approved (8) Terminated (0) Active (12)
✅Levofloxacin + LevofloxacinDr. Reddy's LaboratoriesApproved
✅solifenacin succinate + tamsulosin + placeboAstellas PharmaApproved
✅SolifenacinAstellas PharmaApproved
🔄Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
✅Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)Astellas PharmaApproved
🔄solifenacin succinateAstellas PharmaPhase 3
🔄TamuslosinAstellas PharmaPhase 3

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04144140Phase 1Terminated
NCT04109092Phase 1Withdrawn

Competing Products

20 competing products in Urinary Bladder Neoplasms

See all competitors
ProductCompanyStageHype Score
Levofloxacin + LevofloxacinDr. Reddy's LaboratoriesApproved
36
Duloxetine + placeboEli LillyPhase 2
35
DuloxetineEli LillyPhase 2
35
Enfortumab vedotinAstellas PharmaPhase 1
21
solifenacin succinate + tamsulosin + placeboAstellas PharmaApproved
43
solifenacin succinate + tamsulosin hydrochloride + Placebo to solifenacin + Placebo to tamsulosinAstellas PharmaPhase 2
35
SolifenacinAstellas PharmaApproved
43
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
40
Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)Astellas PharmaApproved
39
solifenacin succinateAstellas PharmaPhase 3
40
SolifenacinAstellas PharmaPre-clinical
26
SolifenacinAstellas PharmaPre-clinical
26
TamuslosinAstellas PharmaPhase 3
40
Tamsulosin + SolifenacinAstellas PharmaApproved
43
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
43
mirabegron 25 mg + mirabegron 50 mg + solifenacin 5 mg + solifenacin 10 mg + mirabegron 25 mg matching placebo + mirabegron 50 mg matching placebo + solifenacin 5 mg matching placebo + solifenacin 10 mg matching placeboAstellas PharmaPhase 3
40
solifenacin succinate + tolterodineAstellas PharmaPhase 3
40
TamusulosinAstellas PharmaPhase 3
40
SolifenacinAstellas PharmaPre-clinical
26
Solifenacin succinate + TolterodineAstellas PharmaPhase 3
40